ClinicalTrialsFinder

Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia Clinical Trials in Zhengzhou, Henan

1 recruitingZhengzhou, Henan, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Primary/Secondary PreventionHigh Risk for Febrile Neutropenia of Chemotherapy RegimensIntermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Henan Cancer Hospital1,076 enrolled1 locationNCT07187908